Dynamk announces Gregory Russotti, Ph.D. as Scientific Advisor

Dr. Gregory Russotti has been announced as the newest member of Dynamk Capital’s Scientific Advisory team of industry experts. Dr. Russotti brings a wealth of knowledge in cell therapy process development and manufacturing. He has a deep understanding of the process challenges faced and the need for innovative tools and technologies to industrialize these new therapeutics. His role at Dynamk includes technical assessment of potential investments in cell therapy and biologics manufacturing and enabling tools for these critical therapeutics.

Dr. Russotti is currently Chief Technical Officer of Century Therapeutics. Before joining Century, he was Vice President of Cell Therapy Development and Operations at Celgene. During his tenure there, he guided CMC efforts for five different cell therapy products to IND and clinical stage development. Greg was also a leader in establishing in-house clinical manufacturing at Celgene, and in building Celgene’s first commercial CAR T manufacturing facility. Greg received his BS and MS degrees in Chemical Engineering from Rensselaer Polytechnic Institute and his PhD in Chemical and Biochemical Engineering from Rutgers University. He has held a visiting professorship in Rutgers Biomedical Engineering department since 2008. Greg also serves as Industrial Executive Board Chairman of the Marcus Center for the Commercialization of Cell Therapies at Georgia Tech, and as an Executive Committee member of the NSF-funded Center for the Manufacturing of Advanced Therapeutics at Georgia Tech.